Aktuality z odborného tisku


Klin Onkol 2015; 28(6): 462-463.

  • Impact of Subsequent Therapies on Outcome of the FIRE-3/ AIO KRK0306 Trial: First-line Therapy with FOLFIRI plus Cetuximab or Bevacizumab in Patients with KRAS Wild-type Tumors in Metastatic Colorectal Cancer

Modest MD, Stintzing S, Weikerstahl LF et al.

J Clin Oncol 2015; 33(32): 3718– 3726. doi: 10.1200/ JCO.2015.61.2887. PubMed PMID: 26261259.


  • Epirubicin plus Cyclophosphamide Followed by Docetaxel versus Epirubicin plus Docetaxel Followed by Capecitabine as Adjuvant Therapy for Node-positive Early Breast Cancer: Results from the GEICAM/ 2003-10 Study

               Martín M, Simón AR, Borrego MR et al.

               J Clin Oncol 2015; 33(32): 3788– 3795. doi: 10.1200/ JCO.2015.61.9510. PubMed PMID: 26416999.


  • Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results from CALGB 89803 (Alliance)

               Guercio BJ, Sato K, Niedzwiecki D et al.

               J Clin Oncol 2015; 33(31): 3598– 3607. doi: 10.1200/ JCO.2015.61.5062. PubMed PMID: 26282659.


  • Blood-brain Barrier Safely Breached

               Lowry F.

               Available from: http:/ / www.medscape.com/ oncology [citováno 19. listopadu 2015].


  • Clinical Outcomes of Elderly Patients Receiving Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

               Jiang DM, Raissouni S, Mercer J et al.

               Ann Oncol 2015; 26(10): 2102– 2106. doi: 10.1093/ annonc/ mdv331. PubMed PMID: 26232491.


  • Prostate Cancer Screening in Men Aged 50– 69 Years (STHLM3): a Prospective Population-based Diagnostic Study

               Grönberg H, Adolfsson J, Aly M et al.

               Lancet Oncol 2015; pii: S1470-2045(15)00361-7. doi: 10.1016/ S1470-2045(15)00361-7. PubMed PMID: 26563502.